Lisata Therapeutics, Inc. (LSTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 3, 2024, by Lisata Therapeutics, Inc. The filing discloses the entry into a Material Definitive Agreement on November 30, 2024, with Kuva Labs, Inc., a wholly-owned subsidiary of Mi2 Holdings, LLC.
Key Financial Metrics and Transaction Terms
The filing details a strategic partnership involving the Company's novel iRGD cyclic peptide, certepetide. Key financial terms of the agreement include:
- Upfront Payment: $1.0 million cash license fee, payable in four installments within 12 months.
- Development Milestones: Up to $1.5 million upon achieving specified regulatory milestones.
- Commercial Milestones: Up to $17.5 million upon achieving specified commercial and net sales milestones.
- Royalties: A flat-rate 5.0% royalty on net sales of Licensed Products, subject to specified reductions.
- Sublicensing: Kuva will pay a portion of any sublicense consideration received.
The filing does not provide current revenue, profit, cash flow, debt, or liquidity metrics for the Company.
Material Changes and Strategic Impact
Under the agreement, Kuva assumes full responsibility for research, development, and commercialization costs for certepetide. Lisata Therapeutics will supply the product for clinical and commercial use. The partnership aims to combine certepetide as a targeting agent with Kuva's NanoMark imaging technology for solid tumors. This represents a significant shift in the commercialization strategy for the Company's lead asset.
Outlook, Risks, and Contingencies
Management Commentary: The agreement is expected to explore synergistic potential between the two companies' technologies.
Termination Rights:
- Either party may terminate for insolvency or material breach.
- Kuva may terminate the entire agreement at any time with 60 days' prior written notice.
Contingencies: If the underlying license with the Sanford Burnham Prebys Medical Discovery Institute (SBP) is terminated, Kuva's license to SBP know-how will also terminate unless Kuva elects to assume the Company's obligations to SBP.
Investor Verification Checklist
- Verify the payment schedule and conditions for the $1.0 million upfront fee.
- Review the specific regulatory and commercial milestones required to trigger the $19.0 million in potential milestone payments.
- Confirm the terms of the Clinical Supply Agreement and the future Commercial Supply Agreement.
- Assess the impact of Kuva's broad termination rights on the long-term value of the partnership.
- Monitor the status of the underlying SBP License Agreement to ensure continuity of the intellectual property rights.